Seaport Therapeutics Starts Phase 2a Trial of GlyphAgo in GAD
Seaport Therapeutics dosed the first patient in a six-week Phase 2a trial of GlyphAgo (SPT-320) in adults with GAD and sleep disturbance in Australia.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.